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Parkinson’s disease (PD), a neurodegenerative disorder, is accompanied by various
non-motor symptoms including depression and anxiety, which may precede the
onset of motor symptoms. Selegiline is an irreversible monoamine oxidase-B (MAO-B)
inhibitor, and is widely used in the treatment of PD and major depression. However,
there are few reports about the effects of selegiline on non-motor symptoms in PD.
The aim of this study was to explore the antidepressant and anxiolytic effects of
selegiline, using CD157/BST1 knockout (CD157 KO) mouse, a PD-related genetic
model displaying depression and anxiety, compared with other antiparkinsonian drugs
and an antidepressant, and was to investigate the effects of selegiline on biochemical
parameters in emotion-related brain regions. A single administration of selegiline
(1–10 mg/kg) dose-dependently reduced immobility time in the forced swimming test
(FST) in CD157 KO mice, but not C57BL/6N wild-type (WT) mice. At 10 mg/kg, but
not 3 mg/kg, selegiline significantly increased climbing time in CD157 KO mice. A
single administration of the antiparkinsonian drugs pramipexole (a dopamine (DA)
D2/D3 receptor agonist) or rasagiline (another MAO-B inhibitor), and repeated injections
of a noradrenergic and specific serotonergic antidepressant (NaSSA), mirtazapine, also
decreased immobility time, but did not increase climbing time, in CD157 KO mice. The
antidepressant-like effects of 10 mg/kg selegiline were comparable to those of 10 mg/kg
rasagiline, and tended to be stronger than those of 1 mg/kg rasagiline. After the FST,
CD157 KO mice showed decreases in striatal and hippocampal serotonin (5-HT)
content, cortical norepinephrine (NE) content, and plasma corticosterone concentration.
A single administration of selegiline at 10 mg/kg returned striatal 5-HT, cortical NE,
and plasma corticosterone levels to those observed in WT mice. In the open field
test (OFT), repeated administration of mirtazapine had anxiolytic effects, and selegiline
nonsignificantly ameliorated anxiety-like behaviors in CD157 KO mice. In the social
interaction and preference tests, repeated mirtazapine ameliorated the high anxiety and
low sociability of CD157 KO mice, whereas selegiline did not. These results indicate that
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selegiline has antidepressant and mild anxiolytic effects in CD157 KO mice, and suggest
that it is an effective antiparkinsonian drug for depressive and anxiety symptoms in PD
patients with a CD157 single nucleotide polymorphism (SNP).
Keywords: CD157/BST-1, Parkinson’s disease, non-motor symptoms, selegiline, mirtazapine, forced swimming
test, open field test
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder characterized by motor symptoms such as bradykinesia,
rigidity, tremor at rest and postural instability, which arise
mainly from dysfunction of the nigrostriatal dopaminergic
pathway (Jankovic, 2008; Braak and Del Tredici, 2009).
PD is also accompanied by non-motor symptoms including
autonomic dysfunction, cognitive and psychiatric abnormalities
(e.g., dementia, depression, apathy, anxiety and hallucination),
sleep disorders and sensory abnormalities (Jankovic, 2008).
Non-motor symptoms in PD correlate with advancing age and
disease severity, although some non-motor symptoms including
olfactory problems, constipation and depression, can occur early
in the disease (Chaudhuri et al., 2006).
Depression and anxiety appear in approximately 40%
(4%–70%) and 50% of all PD patients, respectively (Cummings,
1992; Leentjens et al., 2008). Non-motor symptoms greatly
contribute to a reduced quality of life for patients with PD
(Yamamoto, 2001; Edwards et al., 2002). The classic treatment
L-3,4-dihydroxyphenylalanine (levodopa) has little effect on
most non-motor symptoms (Chaudhuri et al., 2006), and chronic
administration is associated with a risk of depression and anxiety
(Damãsio et al., 1971; Marsh and Markham, 1973; Choi et al.,
2000; Nègre-Pagès et al., 2010; Eskow Jeunarajs et al., 2011).
There are some differences in neural circuitry dysfunction
between major depression and PD-associated depression. For
instance, suicidal tendencies and expression of guilt and
self-blame are rarely observed in depressed PD patients, in
contrast to patients with major depressive disorder (Brooks and
Doder, 2001; Lemke, 2008; Starkstein et al., 2008). Postmortem
studies of brains from PD patients have shown stage-dependent
deposition of aggregated α-synuclein and neuronal loss in
multiple brain areas such as serotonergic neurons in the
raphe nuclei, noradrenergic neurons in the locus coeruleus,
dopaminergic neurons in the substantia nigra and ventral
tegmental area, and cortical neurons in regions interconnected
with limbic structures (Braak et al., 2004). Conversely, brains
from patients with major depression have reductions in
gray-matter volume and glial density in the prefrontal cortex
and hippocampus (Krishnan and Nestler, 2008), and dysfunction
in the prefrontal–subcortical circuits including the amygdala,
ventral striatum, hippocampus and dorsal raphe nucleus (Heller,
2016). One of the key pathophysiological mechanisms in
major depression is impaired negative feedback control of
the hypothalamic–pituitary–adrenal (HPA) axis, resulting in
progressively unrestrained glucocorticoid release (Holsboer,
2000). Sustained elevation of glucocorticoid concentration under
conditions of prolonged and severe stress, which may damage
hippocampal neurons, is not observed in depressed PD patients
(McEwen, 2000; Sapolsky, 2000). Although adequate treatment is
needed for depression and anxiety in PD, their pathophysiology
remains poorly understood.
The classical monoamine hypothesis of depression
suggests that the disorder arises from a deterioration of
noradrenergic/serotonergic function. In depressed PD
patients, there is evidence that levels of norepinephrine
(NE; Braak et al., 2004) and serotonin (5-HT; Kish et al.,
2008) in the brain and/or cerebrospinal fluid are lower than
in healthy people. Serotonergic and noradrenergic neuron
dysfunction occurs even in the preclinical period of PD.
Therefore, noradrenergic and serotonergic systems may play
a significant role in the manifestation of depression and
anxiety in PD. Some clinical studies suggested that tricyclic
antidepressants such as desipramine and reboxetine (NE
reuptake inhibitors), nortriptyline (an NE and 5-HT reuptake
inhibitor) and citalopram (a selective 5-HT reuptake inhibitor)
improved depressive symptoms in PD patients (Devos et al.,
2008; Lemke, 2008; Menza et al., 2009). However, there was
insufficient evidence to support the efficacy of antidepressants
for the treatment of depression in PD (Liu et al., 2013a).
Psychiatric symptoms in PD are still considered difficult to treat,
possibly owing to concerns of exacerbation of parkinsonism by
antidepressants (Leo, 1996). Therefore, a monotherapeutic agent
to treat both motor and non-motor symptoms of PD would be a
valuable therapeutic strategy in early PD, eliminating the risk of
adverse drug interactions.
Bone marrow stromal cell antigen-1 (BST-1) was first isolated
as a cell surface molecule that supported the cell growth
of pre-B cells (Kaisho et al., 1994; Ishihara and Hirano,
2000) and clustered in CD157 in Leucocyte Typing VI after
genetic cloning (Itoh et al., 1994; Muraoka et al., 1996;
Okuyama et al., 1996; Ishihara et al., 1997). CD157/BST-1 is
a member of the NADase/ADP-ribosyl cyclase family, to
which CD38 also belongs (Hirata et al., 1994; Itoh et al.,
1994; Ferrero et al., 1999; Ishihara and Hirano, 2000; Guse,
2005; Malavasi et al., 2006, 2008; Higashida et al., 2012;
Lee, 2012). CD157/BST-1 has a variety of roles in the
humoral immune response, neutrophil transmigration and
hematopoietic stem cell support (Ishihara and Hirano, 2000;
Funaro et al., 2004; Podestà et al., 2005; Malavasi et al.,
2006; Mouchiroud et al., 2013). CD157/BST-1 is also involved
in the pathogenesis of several diseases such as survival
of B lymphocytes in rheumatoid arthritis, progression of
leukemia, and metastasis of human ovarian carcinoma cells
(Kaisho et al., 1994; Shimaoka et al., 1998; Ishihara and
Hirano, 2000; Ortolan et al., 2010; Quarona et al., 2013;
Lo Buono et al., 2014). Recently, genome-wide association
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studies and meta-analyses for PD identified intronic single-
nucleotide polymorphisms (SNPs) in the CD157/BST1 gene
on the human chromosome 4p15 as a new susceptibility
locus in Asian and European populations (Satake et al.,
2009; Tan et al., 2010; Liu et al., 2011, 2013b; International
Parkinson Disease Genomics Consortium et al., 2011; Saad
et al., 2011; Simón-Sánchez et al., 2011; UK Parkinson’s Disease
Consortium et al., 2011; Zimprich, 2011; Lill et al., 2012;
Sharma et al., 2012). In our previous study, CD157/BST1
knockout (CD157 KO) mice showed depression-like behaviors
in the forced swimming test (FST) and the tail suspension
test, anxiety-like behaviors in the open field test (OFT), the
light dark transition test and the elevated plus maze test, and
impaired social behaviors in the social preference test, which
in part resemble psychiatric symptoms observed in patients
with PD (Jankovic, 2008; Kummer et al., 2008). In contrast,
CD157 KO mice did not show any degeneration of nigrostriatal
dopaminergic neurons, any apparent motor dysfunction, or any
alteration in dopaminergic neuron susceptibility to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP; Lopatina et al., 2014).
Genetic and environmental factors may be needed to consider
the real pathogenic role of CD157 SNPs or deletion, as suggested
by a previous study (Chen et al., 2014). And additionally,
we cannot exclude the possibility that psychiatric phenotypes
in CD157 KO mice are related to autism spectrum disorder
(ASD), because it was reported that CD157/BST1 SNPs showed
significant association with ASD (Yokoyama et al., 2015).
Although further studies remain to be carried out in order
to elucidate how CD157 mutation or deletion contributes to
pathogenic process of PD or psychiatric symptoms, our previous
study suggests that young adult CD157 KO mice are possibly
a genetic rodent model for psychiatry symptoms associated
with PD.
Selegiline, a selective and irreversible monoamine oxidase
(MAO)-B inhibitor, is widely used for the treatment of PD
(Birkmayer et al., 1977), as well as for major and atypical
depression at higher doses to inhibit both MAO-A and -B activity
(Varga and Tringer, 1967; Mann and Gershon, 1980; Birkmayer
et al., 1984). MAO-B inhibitors block the metabolism of
dopamine (DA), and increase DA concentration in the synaptic
cleft (Youdim, 2013). DA induces motivation, reward and
hedonic states, and plays an important role in neuropsychiatric
disorders such as depression. Selegiline was reported to have
antidepressant effects mediated by the activation of D1 and
D2 receptors in normal and depressed mice (Shimazu et al., 2005;
Amiri et al., 2016). Moreover, several studies have shown that
selegiline enhances the expression of brain-derived neurotrophic
factor in cultured murine astrocytes and in the anterior cingulate
cortex of mice (Mizuta et al., 2000; Gyárfás et al., 2010), and
prevents dopaminergic neurons from degeneration (Zhu et al.,
2008; Youdim, 2013; Kong et al., 2015). In de novo PD patients,
a double-blind, randomized, placebo-controlled clinical study
demonstrated that selegiline monotherapy improved depression
scores in the Hamilton Depression Rating Scale and the mental
subscale of the Unified PD Rating Scale, and also improved
motor scores (Allain et al., 1993). However, to our knowledge,
there are no reports of the effects of selegiline in animal models
of psychiatric symptoms of PD. In addition, it is not clear whether
the antidepressant effect of selegiline reported in the above-
mentioned clinical study is independent of its effect on motor
symptoms.
Here, we investigated the effect of selegiline on depression-
and anxiety-like behaviors in CD157 KO mice, a PD-related
genetic model, and on biochemical parameters in their
emotion-related brain regions. Furthermore, to clarify whether
antiparkinsonian drugs acting on dopaminergic system have
commonly the antidepressant action, we compared effects of
selegiline on depression-like behavior in CD157 KO mice with
those of the antiparkinsonian drugs rasagiline (another MAO-B
inhibitor) and pramipexole (a D2/D3 receptor agonist). We
demonstrated that selegiline exerted significant antidepressant
effects in a dose-dependent manner and showed a tendency
to improve anxiety-like behavior in CD157 KO mice. The
antidepressant effects of selegiline could be related to an
enhancement in dopaminergic signaling, and normalization




C57BL/6N wild-type (WT) mice were obtained from Japan SLC
Inc. (Shizuoka, Japan). CD157 KO mice were as previously
described (Itoh et al., 1998). WT and CD157 KO colonies were
maintained by crossbreeding WT and homozygous mutant mice,
respectively. For experiments, CD157 KO mice were obtained
by breeding between homozygous mutant mice (Lopatina et al.,
2014). WT and CD157 KO mice were housed at the Institute
for Experimental Animals, Advanced Science Research Center,
Kanazawa University, under standard conditions (22◦C; 12-h
light/dark cycle, lights on at 8:45 a.m.) in standard mouse
cages (300 × 160 × 110 mm) with sawdust bedding, and
food and water ad libitum. Mice were single-housed for
5–7 days before the behavioral tests in order to control for
environmental and social factor on behaviors, and the behavioral
tests were conducted when the mice were 8 weeks old. This
study was carried out in accordance with the Fundamental
Guidelines for Proper Conduct of Animal Experiment and
Related Activities in Academic Research Institutions under the
jurisdiction of the Ministry of Education, Culture, Sports, Science
and Technology of Japan. The protocol was approved by the
Committee on Animal Experimentation of Kanazawa University
(AP-143261).
Drugs
Selegiline hydrochloride (FP Pharmaceutical Co., Osaka, Japan)
was dissolved in saline and administered by single or repeated
(daily for 3 days) subcutaneous (s.c.) injections at a dose
of 1–10 mg/kg, which was the effective dose and treatment
in PD and/or depression rodent models (Fredriksson et al.,
1999; Shimazu et al., 2005). Rasagiline mesylate (Sigma-Aldrich,
St. Louis, MO, USA) was dissolved in saline and administered
in a single s.c. injection at a dose of 1 or 10 mg/kg in
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order to compare the antidepressant effects between these two
MAO-B inhibitors (Finberg and Youdim, 2002; Youdim and
Tipton, 2002). Pramipexole dihydrochloride (Sigma-Aldrich)
was dissolved in saline and administered in a single s.c.
injection at a dose of 1 mg/kg which was reported to be
the effective dose and treatment in PD and/or depression
rodent models (Maj et al., 1997; Siuciak and Fujiwara, 2004;
Kitagawa et al., 2009; Bonito-Oliva et al., 2014). A noradrenergic
and specific serotonergic antidepressant (NaSSA), mirtazapine
(Sigma-Aldrich) was suspended in 0.2% Tween 80 solution
and injected intraperitoneally (i.p.) at a dose of 1 mg/kg
daily for 7 days, based on our preparatory experiments of the
previous study (Lopatina et al., 2014). All drugs or saline were
administered to mice in a volume of 10 mL/kg. Mice were
subjected to behavioral tests 1 h after the last injection of
selegiline, rasagiline, pramipexole or saline, or 30 min after the
last injection of mirtazapine.
Forced Swimming Test (FST)
The FST was performed according to the method originally
described (Porsolt et al., 1977). Mice were placed individually
in a cylinder (height 49 cm, diameter 15 cm) filled with water
(25 ± 1◦C) to a depth of 20 cm, for 6 min. After the initial
2 min of vigorous activity, the total duration of immobility
during the last 4 min of the test was recorded. The duration
of immobility was defined as the time during which the mouse
floated passively, made no attempt to escape and showed only
slow movements to keep its head above the water. The immobile
state was analyzed using a digital video system and ANY-maze
video tracking software (Stoelting, Wood Dale, IL, USA). The
duration of climbing behavior (an emotion-related behavior)
was defined as the time during which the mouse made forceful
thrashing movements with its forelimbs against the walls of the
cylinder during the full 6 min-video recording, and was measured
manually with a stop watch by an unrelated observer (Lopatina
et al., 2014).
Plasma Corticosterone Concentration
Blood samples were collected by cardiac puncture from
isoflurane-anesthetized mice 1 h after the FST or without the
FST exposure, into EDTA-containing tubes. Blood samples
were centrifuged for 15 min at 4◦C and 1000× g, and plasma
samples were stored at−80◦C until assay. Plasma corticosterone
concentrations were measured using corticosterone ELISA kits
(Enzo Lifesciences, Farmingdale, NY, USA), according to the
manufacturer’s instructions.
Open Field Test (OFT)
The OFT was performed as described previously (Lopatina et al.,
2014). The open field chamber consisted of a square wooden
box (550 × 600 × 400 mm), with the inner surfaces covered
with polypropylene sheets. The open field was divided into a
center zone (300 × 300 mm) and periphery. First, a mouse was
placed in the arena for 10 min (session 1), then returned to its
home cage. In session 2, a novel non-social object (a wire cage,
70 × 90 × 70 mm, bars 5 mm apart) was placed in the center
zone. The mouse was placed into the arena with the non-social
object for 10 min, before being returned to its home cage. In
session 3, a naïve male 8-week-old C57BL/6N mouse was placed
under the wire cage. The test mouse was again placed in the arena
for 10 min. The percentage of the time spent in the center zone,
number of entries into the center zone, total distance traveled,
and immobility time were analyzed using a digital video system
and ANY-maze video tracking software. At the end of session 3,
the test chambers were sprayed with 1% sodium hypochlorite and
70% ethanol and cleaned with paper towels. The time interval
between sessions was 2–3 min.
Determination of Monoamines and their
Metabolite Content in Brain
Animals subjected to the FST or OFT were sacrificed by
cervical dislocation after blood collection via cardiac puncture
under isoflurane anesthesia, and their brains were removed
rapidly after decapitation. The cortex, striatum, amygdala
and hippocampus were dissected and stored at −80◦C until
neurochemical quantification. Tissues were homogenized with
a microhomogenizer in 0.2 M perchloric acid containing
isoproterenol (cortex, amygdala and hippocampus, 10 pg/µL;
striatum, 100 pg/µL) as an internal standard. The homogenates
were kept on ice for 30 min and centrifuged for 20 min
at 4◦C and 15,000× g, and the supernatants were passed
through a 0.45 µm filter. All samples were stored at
−80◦C until high performance liquid chromatography (HPLC)
measurement.
The tissue content of DA and its metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine
(3-MT) and homovanillic acid (HVA), 5-HT and its metabolite
5-hydroxyindoleacetic acid (5-HIAA), and NE were measured
in an HPLC-electrochemical detector system (ECD-70,
Eicom Co., Kyoto, Japan). Each 10 µL sample was injected
into a C18 reverse-phase column (Eicompak SC-5ODS:
3.0 mm × 150 mm, Eicom) conditioned at 25◦C. The mobile
phase [0.1 M acetic acid–citric acid buffer (pH 3.5), 15%
methanol, 190 mg/L sodium 1-octanesulfonate and 5 mg/L
EDTA] was delivered at a flow rate of 0.5 mL/min. The
applied potential was set to +750 mV vs. Ag/AgCl. The
tissue content of the monoamines and their metabolites was
calculated using standard curves and expressed as µg/g wet
tissue.
Statistical Analysis
Statistical analyses were performed using SPSS 23.0 (IBM Corp.,
Armonk, NY, USA). The data are expressed as the mean± SEM.
The saline-treated WT mice and the saline-treated CD157 KO
mice were compared using Levene’s test, followed by post hoc
two-tailed Student’s t-tests. Two-way analysis of variance
(ANOVA) was performed to examine the interaction between
the effects of drugs or FST, and genotypes. In each genotype,
comparisons between the saline- and drug-treated groups were
evaluated using one-way ANOVA followed by Dunnett’s test.
The difference was considered statistically significant at a value
of P < 0.05.
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RESULTS
Effects of Selegiline on Depression-Like
Behavior in CD157 KO Mice
Saline-treated CD157 KO mice had significantly longer
immobility times than saline-treated WT mice (t = −2.799,
P < 0.01), indicating that CD157 KO mice exhibited
depression-like behavior, as previously described (Lopatina
et al., 2014). The single administration of selegiline (1–10 mg/kg,
s.c.) significantly reduced the immobility time of CD157 KO
mice in a dose-dependent manner (3 mg/kg, P < 0.05; 10 mg/kg,
P < 0.001). However, a single administration of selegiline did
not influence the immobility time of WT mice at any dose
(Figure 1A). There were no differences in swimming speed
between genotypes or treatment groups (Supplementary Figure).
Climbing time in saline-treated CD157 KO mice was
significantly longer than that in saline-treated WT mice
(t = −3.465, P < 0.005). A single administration of selegiline at
10 mg/kg, but not 3 mg/kg, significantly increased climbing time
in CD157 KO mice (P < 0.05; Figure 1B).
Effects of MAO-B Inhibitors, a DA Agonist
and a NaSSA on a Depression-Like
Behavior in CD157 KO Mice
For the next set of experiment, we evaluated the effects of other
monoaminergic compounds currently used in the treatment
of PD and major depression on depression-like behavior in
CD157 KO mice. To evaluate the predictive validity and the
involvement of DA signaling in depression-like behavior in
CD157 KO mice, we used 1 mg/kg pramipexole, which is
an effective dose in animal models of PD and depression
(Maj et al., 1997; Siuciak and Fujiwara, 2004; Kitagawa et al.,
2009; Bonito-Oliva et al., 2014). Another MAO-B inhibitor,
rasagiline, is reported to be 3–15 times more potent in MAO-B
inhibition than selegiline in rats (Youdim et al., 2001), and has a
levodopa equivalent dose (LED) one-tenth of that of selegiline
in patients with PD (Tomlinson et al., 2010). In addition,
there are some pharmacological differences in DA reuptake
inhibition (Lamensdorf et al., 1999) and preferentially inducible
neurotrophic factors (Naoi et al., 2013) between these MAO-B
inhibitors. Therefore, 1 and 10 mg/kg rasagiline was selected for
comparison with 10 mg/kg selegiline, which had shown effects
on depression-like behavior and climbing (Figures 1A,B), as
well as having antiparkinsonian effects in several rodent models
(Fredriksson et al., 1999; Callizot et al., 2001; Leret et al., 2002;
Rajendra Kopalli et al., 2012). Dosage of the NaSSA mirtazapine
was 1 mg/kg i.p. daily for 7 days, at which it ameliorated
depression- and anxiety-like behaviors in CD157 KO mice, based
on our preparatory experiments of the previous study (Lopatina
et al., 2014).
Pramipexole (single injection of 1 mg/kg, s.c.) and
mirtazapine (repeated injections of 1 mg/kg, i.p., daily for
7 days) reduced the elevated immobility time in CD157 KO
mice (pramipexole, P < 0.001; mirtazapine, P < 0.05). The
antidepressant-like effect of 10 mg/kg selegiline was comparable
to that of the same dose of rasagiline, and tended to be
stronger than the effect of 1 mg/kg rasagiline (t = −1.602,
P = 0.120; Figure 1C). There were no differences in swimming
speed between treatment groups (data not shown). Selegiline
(10 mg/kg, s.c.) increased climbing time in CD157 KO mice
(P < 0.001), whereas rasagiline, pramipexole and mirtazapine
did not significantly influence climbing time (Figure 1D).
Effects of Selegiline on Plasma
Corticosterone Concentrations in CD157
KO Mice Subjected to the FST
Stress adaptation failure is one of the primary neuropathological
causes of depression (McEwen, 2000). Hyperactivity of the
HPA axis, which results in elevated glucocorticoid levels, is
consistently observed in depressed patients (Herman et al.,
2003; de Kloet et al., 2005). In contrast, patients with
PD and depression have significantly lower baseline levels
of corticosterone than those with major depression alone,
indicating that stress responses may be differentially regulated
in these two patient populations (Pålhagen et al., 2010). We
therefore measured plasma corticosterone concentrations in WT
and CD157 KO mice with or without FST exposure. There were
no differences in baseline plasma corticosterone concentrations
between WT and CD157 KO mice. The FST induced significant
increases in plasma corticosterone concentrations in both
genotypes (WT mice, P < 0.001; CD157 KO mice, P < 0.001).
Interestingly, plasma corticosterone concentrations in CD157
KO mice subjected to the FST were lower than those in WT mice
(P = 0.062, Figure 2A; t = 2.874, P < 0.01, Figure 2B).
The single administration of selegiline (1 or 10 mg/kg,
s.c.) 1 h before the FST significantly elevated post-FST plasma
corticosterone concentrations in CD157 KO mice, to levels
comparable to those in WT mice (P < 0.05). In contrast,
selegiline (1–10 mg/kg, s.c.) did not influence the FST-induced
increase in plasma corticosterone in WT mice (Figure 2B).
Effects of Selegiline and Mirtazapine on
Anxiety-Like and Social Behaviors in
CD157 KO Mice
The OFT, which measures approach to or avoidance of a central
area is a commonly used and pharmacologically validated test
for evaluating anxiety in a novel environment (Ramos and
Mormède, 1998). In our previous studies, CD157 KO mice
displayed severe anxiety-like behaviors in the novel environment
and in the presence of a novel non-social object, and a weak
sociability against a social target in the OFT, and an abnormal
sociability in a three-chamber paradigm (Lopatina et al., 2014;
Mizuno et al., 2015; Higashida et al., 2017). We therefore
evaluated the effects of repeated administration of selegiline
and mirtazapine on anxiety-like behaviors, including sociability-
related anxiety and social preference tasks in WT and CD157
KO mice, using the OFT (Figure 3). In session 1, the number
of entries into the center zone, and the percentage of time
spent in the center zone, were lower in saline-treated CD157
KO mice than in saline-treated WT mice (number of entries,
t = 2.449, P < 0.05; percentage of time spent, t = 2.770,
P < 0.05; Figures 3A,B), confirming the anxiety-like behavior
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FIGURE 1 | Effects of monoamine oxidase-B (MAO-B) inhibitors, a dopamine (DA) agonist and a noradrenergic and specific serotonergic
antidepressant (NaSSA) on a depression-like behavior in CD157/BST1 knockout (CD157 KO) mice subjected to the forced swimming test (FST). (A) A
single administration of selegiline (1−10 mg/kg, subcutaneous, s.c.) reduced immobility time of CD157 KO mice in the FST. ∗∗P < 0.01, saline-treated CD157 KO
mice vs. saline-treated wild-type (WT) mice (Student’s t-test), #P < 0.05, ####P < 0.001 vs. saline-treated CD157 KO mice (Dunnett’s test), F(3,64) = 12.539,
P < 0.001. A two-way analysis of variance (ANOVA) showed a significant interaction between the effects of treatment and genotypes on the immobility time
(F(3,128) = 3.904, P < 0.05). (B) A single s.c. administration of selegiline at 10 mg/kg, but not 3 mg/kg, significantly increased climbing time of CD157 KO mice. The
data are expressed as the mean ± SEM (n = 21−22 for saline-treated WT and CD157 KO mice, n = 15−17 for selegiline-treated WT and CD157 KO mice).
∗∗∗P < 0.005, saline-treated CD157 KO mice vs. saline-treated WT mice (Student’s t-test), #P < 0.05 vs. saline-treated CD157 KO mice (Dunnett’s test),
F(3,67) = 4.382, P < 0.01. A two-way ANOVA showed no significant interaction between the effects of treatment and genotypes on the climbing time
(F(3,131) = 1.684, P = 0.174). (C) A single administration of selegiline (Sel; 10 mg/kg, s.c.), rasagiline (Ras; 1, 10 mg/kg, s.c.), or pramipexole (Ppx; 1 mg/kg, s.c.) and
repeated administration of mirtazapine (Mir; 1 mg/kg, intraperitoneally, i.p.) reduced immobility time of CD157 KO mice in the FST. ∗∗∗P < 0.005, saline-treated
CD157 KO mice vs. saline-treated WT mice (Student’s t-test), #P < 0.05, ####P < 0.001 vs. saline-treated CD157 KO mice (Dunnett’s test), F(5,86) = 10.276,
P < 0.001. (D) Selegiline (10 mg/kg, s.c.) increased the climbing time of CD157 KO mice, but rasagiline, pramipexole and mirtazapine did not. Data are expressed
as mean ± SEM (n = 22−24 for saline-treated WT and CD157 KO mice, n = 12−19 for drug-treated CD157 KO mice). ∗∗∗P < 0.005, saline-treated CD157 KO mice
vs. saline-treated WT mice (Student’s t-test), ####P < 0.001 vs. saline-treated CD157 KO mice (Dunnett’s test), F(5,87) = 8.471, P < 0.001.
in CD157 KO mice described previously (Lopatina et al., 2014).
There were no differences between genotypes or treatment
groups in total distance traveled (Figure 3C). CD157 KO mice
that received repeated selegiline (1 mg/kg daily for 3 days)
showed a tendency toward a higher number of entries into
the center zone than those that received saline (P = 0.111;
Figure 3A), suggesting that selegiline, administered repeatedly,
has a tendency to reduce the elevated anxiety levels in CD157 KO
mice placed in a novel environment. The single administration
of selegiline (1–10 mg/kg, s.c.), however, did not influence
anxiety-like behaviors in CD157 KO mice (data not shown),
suggesting that repeated exposure to selegiline may be required
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FIGURE 2 | Effects of selegiline on plasma corticosterone concentrations in CD157 KO mice subjected to the FST. (A) The FST induced a significant
increase in plasma corticosterone concentrations in both WT and CD157 KO mice, and plasma corticosterone concentrations in WT mice after the FST were higher
than those of CD157 KO mice. There were no significant differences in baseline plasma corticosterone concentrations between WT and CD157 KO mice. Data are
expressed as mean ± SEM (n = 11−16). ∗∗∗∗P < 0.001 vs. non-treatment mice and +P = 0.062 vs. WT after FST (Dunnett’s test). A two-way ANOVA showed main
effects of FST (F(1,49) = 50.861, P < 0.001) and genotype (F(1,49) = 4.632, P < 0.05) without significant interaction between the effects of FST and genotypes on
plasma corticosterone concentrations (F(1,49) = 0.858, P = 0.359). (B) A single administration of selegiline (1−10 mg/kg, s.c.) elevated post-FST plasma
corticosterone concentrations in CD157 KO mice to the WT post-FST level. Data are expressed as mean ± SEM (n = 10−12). ∗∗P < 0.01, saline-treated CD157 KO
mice vs. saline-treated WT mice (Student’s t-test), #P < 0.05 vs. saline-treated CD157 KO mice (Dunnett’s test), F(3,40) = 3.100, P < 0.05. Selegiline (3 mg/kg, s.c.)
nonsignificantly elevated post-FST plasma corticosterone concentrations in CD157 KO mice (P = 0.051). A two-way ANOVA showed no statistically significant
interaction between the effects of selegiline and genotypes on plasma corticosterone concentration (F(3,81) = 2.025, P = 0.117).
for its anxiolytic effect. Repeated administration of mirtazapine
(1 mg/kg daily for 7 days) resulted in a significant increase
in the number of entries into the center zone, and a decrease
in immobility time of CD157 KO mice (number of entries,
P < 0.05; immobility time, P < 0.05; Figures 3A,D), but failed
to increase the percentage of time the CD157 KO mice spent in
the center zone (Figure 3B). These results indicated that repeated
administration of mirtazapine improved anxiety-like behavior in
CD157 KO mice in the novel environment at the dose at which
antidepressant-like effects were exerted.
Next, we performed the social interaction and preference
tests in the same apparatus. In session 2 (non-social target)
and session 3 (social target), saline-treated CD157 KO mice
showed significant decreases in the number of entries into the
center zone and the percentage of time spent in it, as well
as in the total distance traveled, in comparison with saline-
treated WT mice (number of entries, t = 4.167, P < 0.001,
Figure 3E; t = 2.978, P < 0.01, Figure 3I; percentage of time
spent, t = 3.344, P < 0.01, Figure 3F; t = 2.125, P < 0.05,
Figure 3J; total distance traveled, t = 2.771, P < 0.05, Figure 3G;
t = 2.775, P < 0.05, Figure 3K). Immobility time in saline-
treated CD157 KO mice was significantly longer than in
saline-treated WT mice (t = −3.458, P < 0.005, Figure 3H;
t = −3.023, P < 0.01, Figure 3L). These results indicate that
CD157 KO mice exhibit higher levels of anxiety toward the
novel non-social and social objects, as well as social avoidance.
In session 2 (non-social target), repeated administration of
mirtazapine significantly increased the number of the entries
into the center zone (P < 0.001; Figure 3E), the percentage
of time spent in the center zone (P < 0.001; Figure 3F) and
the total distance traveled (P < 0.01; Figure 3G), and reduced
immobility time in CD157 KO mice (P < 0.005; Figure 3H). In
session 3 (social target), repeated administration of mirtazapine
significantly increased the percentage of time spent in the center
zone (P < 0.05; Figure 3J), decreased immobility time (P < 0.05;
Figure 3L) in CD157 KO mice. These findings suggest that
repeated administration of mirtazapine at 1 mg/kg for 7 days
ameliorates the excess anxiety and low sociability of CD157 KO
mice. In contrast, repeated administration of selegiline at 1 mg/kg
for 3 days had no effect on elevated levels of anxiety and social
avoidance (Figures 3E-L).
Changes in DA, 5-HT, NE and their
Metabolites in Several Brain Regions of
WT and CD157 KO Mice after the FST, and
Effects of a Single Administration of
Selegiline
We evaluated the effects of selegiline on DA, 5-HT, and NE
content, and their metabolites and turnover rates, in depression-
and anxiety-related brain regions (cortex, striatum, amygdala
and hippocampus) of WT and CD157 KO mice after exposure
to the FST (Figure 4). Saline-treated CD157 KO mice had
significantly lower levels of 5-HT in the striatum (t = 3.689,
P < 0.005) and hippocampus (t = 3.052, P < 0.05; Figure 4C),
and NE in the cortex (t = 2.795, P < 0.05; Figure 4F), than
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FIGURE 3 | Effects of selegiline and mirtazapine on anxiety-like and social behaviors in CD157 KO mice. (A−D) In session 1 (novel environment), CD157
KO mice showed anxiety-like behavior compared with WT mice: significantly fewer entries into the center zone (A) and less time spent in the center zone (B).
Repeated administration of selegiline (1 mg/kg, s.c.) for 3 days showed a tendency to increase the number of entries into the center zone (A) in CD157 KO mice.
Repeated administration of mirtazapine (1 mg/kg, i.p.) for 7 days significantly increased the number of entries into the center zone (A). There were no differences in
measured values between genotypes and treatments in total distance traveled (C). Immobility time in CD157 KO mice was longer than that in WT mice. Mirtazapine
reduced immobility time of CD157 KO mice to that of WT mice (D). (E−H) In session 2 (non-social target), CD157 KO mice showed a significant decrease in the
number of entries into the center zone (E), percentage of time spent in the center zone (F) and total distance traveled (G) and a significant increase in immobility
(Continued)
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FIGURE 3 | Continued
time (H) Mirtazapine, but not selegiline, significantly increased the number of
entries into the center zone (E) and percentage of time spent in the center
zone (F) in CD157 KO mice. Mirtazapine significantly increased the total
distance traveled (G), and reduced prolonged immobility time (H) in
saline-treated CD157 KO mice. (I−L) In session 3 (social target), CD157 KO
mice showed significantly lower sociability than WT mice: significant decreases
in the number of entries into the center zone (I), percentage of time spent in
the center zone (J) and total distance traveled (K), and a significant increase in
immobility time (L). Mirtazapine significantly increased the percentage of time
spent in the center zone (J) and decreased immobility time (L), whereas
selegiline did not alter the low-social behavior of CD157 KO mice (I−L). Data
are expressed as mean ± SEM (n = 11−12 for saline-treated WT and CD157
KO mice and selegiline-treated KO mice, n = 7−8 for mirtazapine-treated
CD157 KO mice). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005, ∗∗∗∗P < 0.001,
saline-treated CD157 KO mice vs. saline-treated WT mice (Student’s t-test);
#P < 0.05, ##P < 0.01, ###P < 0.005, ####P < 0.001 vs. saline-treated CD157
KO mice (Dunnett’s test). (A) F(2,29) = 3.711, P < 0.05; (B) F(2,29) = 1.874,
P = 0.172; (C) F(2,29) = 2.227, P = 0.126; (D) F(2,29) = 3.537, P < 0.05;
(E) F(2,29) = 9.018, P < 0.005; (F) F(2,29) = 13.980, P < 0.001;
(G) F(2,29) = 5.932, P < 0.01; (H) F(2,29) = 8.249, P < 0.005;
(I) F(2,28) = 2.397, P = 0.109; (J) F(2,28) = 4.810, P < 0.05; (K) F(2,28) = 2.188,
P = 0.131; (L) F(2,28) = 4.804, P < 0.05.
saline-treated WT mice, as well as higher levels of 5-HIAA in
the amygdala (t = −2.399, P < 0.05; Figure 4D) without a
significant increase in 5-HT turnover rate (Figure 4E). These
data suggest that CD157 KO mice have serotonergic and
noradrenergic dysfunction in depression- and anxiety-related
brain regions, but do not have dopaminergic dysfunction in
the striatum, a region related to the motor symptoms of PD
(Figures 4A,B).
Compared with saline, a single administration of selegiline
(1–10 mg/kg, s.c.) increased DA content in the striatum in
WT and CD157 KO mice after the FST (WT mice: 1 mg/kg,
P < 0.05; 3 mg/kg, P < 0.005; 10 mg/kg, P < 0.001; CD157 KO
mice: 10 mg/kg, P < 0.005) and in the hippocampus (WT mice:
10 mg/kg, P < 0.005; CD157 KO mice: 10 mg/kg, P < 0.005;
Figure 4A). In addition, striatal DA turnover (ratio of DA
metabolites to DA) decreased in 10 mg/kg selegiline-treated WT
(P < 0.01) and CD157 KO mice (P < 0.05; Figure 4B). These
data suggest that a single administration of selegiline produces
increases in striatal DA content mediated by MAO-B inhibition.
A single selegiline injection also dose-dependently increased
cortical NE content (P < 0.05; Figure 4F). Furthermore,
10 mg/kg selegiline recovered the decreased striatal 5-HT content
in CD157 KO mice (P < 0.01; Figure 4C) without a significant
decrease in 5-HIAA content and 5-HT turnover (Figures 4D,E).
Thus, the antidepressant effects of selegiline may be mediated by
enhancement of monoaminergic transmission.
Changes in DA, 5-HT, NE and their
Metabolites in Several Brain Regions of
WT and CD157 KO Mice after the OFT, and
Effects of Repeated Administration of
Selegiline and Mirtazapine
We measured changes in DA, 5-HT and NE content, and their
metabolites and turnover rates, in the cortex, striatum, amygdala
and hippocampus of WT and CD157 KO mice after exposure to
the OFT (Figure 5). We also examined the effects of repeated
administration of 1 mg/kg selegiline for 3 days and 1 mg/kg
mirtazapine for 7 days. In saline-treated CD157 KO mice, 5-HT
content in the cortex and amygdala was significantly lower than
in saline-treated WT mice (cortex: t = 2.248, P< 0.05; amygdala:
t = 2.437, P < 0.05, Figure 5C). There were no differences in
DA, NE and 5-HIAA content, and their turnover rates between
genotypes or treatment groups (Figures 5A,B,D–F). Together,
these data suggest that CD157 KO mice have serotonergic
dysfunction in different brain regions, regardless of the type of
stress to which they are exposed.
Repeated administration of neither selegiline nor
mirtazapine ameliorated the decreases observed in CD157
KO mice in 5-HT content in the cortex and amygdala
(Figure 5C).
DISCUSSION
Depression and anxiety are common non-motor symptoms in
patients with PD, and have a detrimental effect on quality of
life (Yamamoto, 2001; Edwards et al., 2002). Attributed to the
monoaminergic dysfunction of PD, depression and anxiety in
patients with PD are commonly treated with antidepressants
for major depression. However, there is insufficient evidence
for the efficacy and safety of this approach (Shabnam et al.,
2003; Liu et al., 2013a). In the present study, after exposure to
the FST, CD157 KO mice had lower striatal and hippocampal
5-HT content and cortical NE content than WT mice.
Administration of selegiline showed a recovery in forced
swimming stress-induced decreases in striatal 5-HT and cortical
NE concentrations in CD157 KO mice to those in WT mice.
Although no differences between genotypes were detected
in DA content or turnover in the brain regions examined
(cortex, striatum, amygdala and hippocampus) after the FST,
the dopaminergic agents pramipexole, selegiline and rasagiline
alleviated depression-like behavior in CD157 KO mice. This
suggests that depression-like behavior in CD157 KO mice is
associated with dopaminergic dysfunction in brain regions we
did not examine, such as the mesolimbic pathway. Thus, these
data suggest that forced swimming stress leads to serotonergic,
and noradrenergic dysfunction in CD157 KO mice, and that
pharmacological modification of monoaminergic functions may
exert antidepressant effects in CD157 KO mice.
The enzyme MAO exists as two distinct subtypes, MAO-A
and B, the former having a higher affinity for NE and 5-HT,
and the latter for phenylethylamine. DA is a substrate of both
enzymes. In CD157 KO mice, the selective MAO-B inhibitor
selegiline (3 and 10 mg/kg) significantly reduced immobility
time in the FST, and at 10 mg/kg increased striatal and
hippocampal DA content and decreased striatal DA turnover
after the FST. Moreover, 10 mg/kg selegiline normalized
FST-induced decreases in striatal 5-HT and cortical NE content
after the FST in CD157 KO mice. The antidepressant effects
of selegiline in the FST may be mediated by the activation
of D1 receptors (Shimazu et al., 2005; Amiri et al., 2016).
Our data therefore suggest that the antidepressant effect of
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FIGURE 4 | Changes in DA, serotonin (5-HT), norepinephrine (NE) and their metabolites in several brain regions of WT and CD157 KO mice after the
FST, and effects of a single administration of selegiline. Data are shown for DA (A), ratio of DA metabolites to DA (B), 5-HT (C), 5-hydroxyindoleacetic acid
(5-HIAA) (D), 5-HIAA/5-HT ratio (E) and NE (F) in µg/g wet tissue (mean ± SEM; n = 6−9). ∗P < 0.05, ∗∗∗P < 0.005, saline-treated CD157 KO mice vs.
saline-treated WT mice (Student’s t-test); &P < 0.05, &&P < 0.01, &&&P < 0.005, &&&&P < 0.001 vs. saline-treated WT mice (Dunnett’s test); #P < 0.05, ##P < 0.01,
###P < 0.005 vs. saline-treated CD157 KO mice (Dunnett’s test). (A) WT mice (striatum): F(3,30) = 14.106, P < 0.001; CD157 KO mice (striatum): F(3,29) = 5.833,
P < 0.005; WT mice (hippocampus): F(3,30) = 5.315, P < 0.01; CD157 KO mice (hippocampus): F(3,29) = 6.113, P < 0.005; (B) WT mice (striatum): F(3,30) = 5.708,
P < 0.005; CD157 KO mice (striatum): F(3,29) = 3.531, P < 0.05; (C) CD157 KO mice (striatum): F(3,29) = 4.881, P < 0.01; (F) WT mice (cortex): F(3,30) = 3.358,
P < 0.05; CD157 KO mice (cortex):F(3,29) = 4.415, P < 0.05. A two-way ANOVA showed no significant interaction between the effects of treatment and genotypes
on monoamine content or their metabolites in brain regions examined [cortex: F(3,59) = 0.138, P = 0.937; striatum: F(3,59) = 0.372, P = 0.774; amygdala:
F(3,56) = 1.127, P = 0.346; hippocampus: F(3,59) = 0.927, P = 0.434, (A); cortex: F(3,59) = 0.662, P = 0.579; striatum: F(3,59) = 0.832, P = 0.482; amygdala:
F(3,56) = 0.226, P = 0.878; hippocampus: F(3,59) = 0.751, P = 0.526, (B); cortex: F(3,59) = 0.870, P = 0.462; striatum: F(3,59) = 0.901, P = 0.446; amygdala:
F(3,56) = 0.028, P = 0.994; hippocampus: F(3,59) = 0.466, P = 0.707, (C); cortex: F(3,59) = 0.683, P = 0.556; striatum: F(3,59) = 0.308, P = 0.819; amygdala:
F(3,56) = 0.441, P = 0.724; hippocampus: F(3,59) = 0.420, P = 0.739, (D); cortex: F(3,59) = 0.615, P = 0.608; striatum: F(3,59) = 0.055, P = 0.983; amygdala:
F(3,56) = 0.157, P = 0.925; hippocampus: F(3,59) = 0.671, P = 0.573, (E); cortex: F(3,59) = 0.004, P = 1.000; striatum: F(3,59) = 0.069, P = 0.976; amygdala:
F(3,56) = 0.010, P = 0.999; hippocampus: F(3,59) = 1.329, P = 0.274, (F)].
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FIGURE 5 | Changes in DA, 5-HT, NE and their metabolites in several brain regions of WT and CD157 KO mice after the open field test (OFT), and
effects of repeated administration of selegiline and mirtazapine. Data are shown for DA (A), ratio of DA metabolites to DA (B), 5-HT (C), 5-HIAA (D),
5-HIAA/5-HT ratio (E) and NE (F) in µg/g wet tissue as the mean ± SEM (n = 8 for saline-treated WT and CD157 KO mice and selegiline-treated CD157 KO mice,
n = 4 for mirtazapine-treated CD157 KO mice). ∗P < 0.05, saline-treated CD157 KO mice vs. saline-treated WT mice (Student’s t-test).
selegiline is attributable at least partially to the improvement
of serotonergic, noradrenergic and dopaminergic dysfunction in
CD157 KO mice. From the point of view of effective doses of
selegiline, its antidepressant efficacy would be greater in CD157
KO mice than in WT mice or in the normal male ddY mice
used by Shimazu et al. (2005). The difference in the effective
doses of selegiline between the respective genotypes might arise
from changes in monoaminergic dysfunction and/or expression
of depression- and anxiety-associated proteins in CD157 KO
mice, suggesting that an effective dose of selegiline for the
treatment of depression in PD may be lower than that in major
depression.
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Selegiline (3 and 10 mg/kg) significantly reduced immobility
time in CD157 KO mice, and at 10 mg/kg increased climbing
time. Single administration of selegiline at 10 mg/kg did not
influence the swimming speed of CD157 KO mice in the
FST (Supplementary Figure) or the total distance traveled
in the OFT in CD157 KO mice (data not shown). These
data suggest that selegiline’s antidepressant effects do not
necessarily result from increasing climbing behavior and are
not elicited by stimulating motor activity, unlike stimulants
such as methamphetamine, which reduces immobility time
in the FST by causing hyperlocomotion (Kitada et al., 1981;
Shimazu et al., 2005). Interestingly, treatment with rasagiline,
pramipexole or mirtazapine did not increase climbing time in
CD157 KO mice, suggesting that the mechanisms underlying
their antidepressant effects are different from those of selegiline.
Several groups have demonstrated that NE reuptake inhibitors
increase climbing behavior in the FST (Rénéric et al., 2002a,b;
Cryan et al., 2005). In the present study, there was no significant
correlation between cortical NE content in selegiline-treated
CD157 KO mice and their climbing time (data not shown),
despite a dose-dependent increase in cortical NE content.
Although a 50% inhibitory dose on striatal MAO-A activity is
approximately 2.5 mg/kg for both selegiline and rasagiline in
rats following i.p. administration (Youdim and Tipton, 2002),
at 10 mg/kg, selegiline but not rasagiline significantly increased
climbing time in CD157 KO mice. Therefore, the increase in
climbing time by selegiline might be related to an enhancement
in noradrenergic transmission by other mechanisms such as
monoamine reuptake inhibition (Lamensdorf et al., 1999) in
brain regions we did not examine. It is widely accepted that
climbing behavior in the FST is a specific activity aimed at
escaping from the cylinder, and is one of the indexes for
antidepressant-like behavior (Cryan et al., 2005; Perona et al.,
2008), but we speculate that the increase in climbing time
in CD157 KO mice potentially reflects an altered emotional
state (Lopatina et al., 2014). Therefore, the emotional state
in which saline-treated CD157 KO mice are motivated to try
climbing may be qualitatively different from that in selegiline-
treated CD157 KO mice. Further investigation is required
to clarify the meaning of climbing behavior in CD157 KO
mice.
Rasagiline is more potent as an MAO-B inhibitor than
selegiline, and has a similar selectivity for MAO-B over MAO-A
in vivo (Youdim et al., 2001). Its LED for motor symptoms in
patients with PD is one-tenth of selegiline’s LED (Tomlinson
et al., 2010). In CD157 KO mice, the antidepressant-like effects
of selegiline at 10 mg/kg had a tendency to be more potent
than those of rasagiline at 1 mg/kg (t = −1.602, P = 0.120;
Figure 1C), suggesting that selegiline is probably more effective
for ameliorating depression in PD patients than rasagiline at
doses that are therapeutically effective for the motor symptoms
of PD. It also suggests that the MAO inhibition cannot entirely
account for the antidepressant effects of selegiline. Our data are
in line with clinical studies that selegiline improved Hamilton
Depression Rating Scale scores in de novo PD patients (Allain
et al., 1993), but rasagiline was not effective on Beck Depression
Inventory scores (Barone et al., 2015).
There is insufficient evidence to support the efficacy of
mirtazapine on depression and anxiety in PD patients, although
its antidepressant effect in major depression is comparable
to that of tricyclic antidepressants (Watanabe et al., 2011),
which might be effective in PD-related depression (Devos
et al., 2008; Lemke, 2008; Menza et al., 2009). In CD157
KO mice, repeated administration of mirtazapine ameliorated
depression-like behavior in the FST, and anxiety-like behavior
and low sociability in the OFT. These results are consistent
with the effects of mirtazapine in the tail suspension test and
in the elevated plus maze test shown in our previous study
(Lopatina et al., 2014). CD157 KO mice showed decreases in
5-HT content in the cortex and amygdala, following the OFT, but
mirtazapine failed to influence monoaminergic dysfunction in
these brain regions in CD157 KO mice. Therefore, mechanisms
underlying anxiety and low sociability of CD157 KO mice and
anxiolytic effects of mirtazapine may be attributable principally
to other monoaminergic systems, non-monoaminergic systems
or neuroplasticity-associated protein expression (Ishima et al.,
2014; Kadoguchi et al., 2014; Bittolo et al., 2016).
Like other inescapable stress paradigms, the FST elevates
blood corticosterone concentrations in rodents (Steiner et al.,
2008; Rogóz et al., 2012). Interestingly, plasma corticosterone
concentrations after the FST were lower in CD157 KO
mice than in WT mice, although there were no significant
differences in baseline levels between genotypes (Figures 2A,B).
Surprisingly, following the FST in CD157 KO mice, selegiline
(1−10 mg/kg) normalized plasma corticosterone concentrations
to those in WT mice (Figure 2B). Selegiline has a tendency to
ameliorate dose-dependently the depression-like behavior and
post-FST monoamine levels, but not post-FST corticosterone
concentrations, in CD157 KO mice, suggesting that such
effect of selegiline on post-FST corticosterone concentrations
in CD157 KO mice is independent of enhancement of
monoaminergic function in brain regions examined. Inputs
from the amygdala elicit activation of the HPA axis (Sandi,
2004), and amygdala-lesioned rats show significantly lower
plasma corticosterone and adrenocorticotropic hormone levels
after certain types of stress than intact animals (Feldman and
Conforti, 1981; Beaulieu et al., 1987). In our previous study,
the amygdala in CD157 KO mice seemed to be smaller than
in WT mice (Lopatina et al., 2014); therefore, atrophy of
the amygdala in CD157 KO mice might be related to the
reduction in plasma corticosterone concentrations following
the FST. Moreover, amygdala dysfunction in CD157 KO
mice may also be related to their anxiety and depression-like
behavior, because abnormalities in the amygdala might be
involved in PD progression and may contribute to elicitation
of non-motor symptoms such as anxiety and depression in
PD (Huang et al., 2015; van Mierlo et al., 2015; Vriend et al.,
2016). Thus, selegiline may ameliorate depressive symptoms by
normalizing the hypoactivity of the HPA axis arising from the
amygdala.
CD157 KO mice had higher levels of anxiety in the novel
environment (session 1) and toward a novel non-social object
(session 2) than WT mice, confirming previous results (Lopatina
et al., 2014; Mizuno et al., 2015). Moreover, when a novel
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object was placed in the apparatus (session 2), CD157 KO
mice showed a higher level of anxiety than in session 1
(percent of time in center zone in Figure 3B vs. Figure 3F,
t = 2.794, P < 0.05). In the experiments with a social
target (session 3), CD157 KO mice seemed more nervous
than WT mice, and showed weak sociability to the novel
mouse, which is characteristic of their phenotype (Lopatina
et al., 2014). Furthermore, their phenotype is possibly in line
with clinical descriptions of social phobia occurring in 50%
of PD patients (Kummer et al., 2008), and depressed PD
patients having significantly fewer social ties than non-depressed
PD patients (Starkstein et al., 1990). Repeated injection of
selegiline at 1 mg/kg for 3 days had a tendency to improve
the anxiety-like behavior of CD157 KO mice in the novel
environment (session 1), but did not alleviate the higher level of
anxiety toward a novel non-social object (session 2) or the weak
sociability to the novel social target (session 3). This suggests that
selegiline improves mild anxiety but not severe anxiety or low
sociability.
In the present study, there was a moderate negative
correlation between 3-MT/DA ratio in the cortex and amygdala
and immobility time in saline and selegiline-treated CD157 KO
mice in the FST (cortex, r = −0.496, P < 0.005; amygdala,
r = −0.499, P < 0.01). At 10 mg/kg, selegiline increased the
3-MT/DA ratio in the cortex, amygdala and hippocampus,
and reduced the DOPAC/DA ratio in the cortex, striatum
and amygdala (data not shown), probably resulting from brain
MAO-B inhibition. Intracerebroventricular administration of
3-MT increases behavioral activity (Nakazato and Akiyama,
2002; Sotnikova et al., 2010), and 3-MT and phenylethylamine
have affinity for trace amine-associated receptor 1, which is
involved in neuropsychiatric disorders including depression (Shi
et al., 2016). Therefore, the antidepressant effect of selegiline
might be mediated via MAO-B inhibition-induced enhancement
of 3-MT and phenylethylamine content.
In conclusion, mice lacking a PD-related gene CD157 show
the depression- and anxiety-like behaviors and impairment
of their brain monoamine content after exposure to stress.
Selegiline exerted some anxiolytic effects in addition to
antidepressant effects in CD157 KO mice. These results highlight
the potential of selegiline as an antiparkinsonian agent with
the efficacy in CD157 mutation-related depressive and anxiety
symptoms.
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